

Rosuvastatin (CRESTOR®)

(No. 45/03)

AstraZeneca

Summary of Recommendation

4 April 2003 (*Amended 24 Oct 2011*)

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE

Recommended for general use within NHS Scotland.

INDICATIONS UNDER REVIEW

- primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet, when response to diet and exercise is inadequate.
- homozygous familial hypercholesterolaemia, either alone or as an adjunct to diet and other lipid-lowering treatments (e.g. LDL apheresis).

RECOMMENDATION

Rosuvastatin is a new HMG-CoA reductase inhibitor, with costs and efficacy in reducing low-density-lipoprotein-cholesterol (LDL-C) comparable to other statins. Its current licenced indications are more limited than some other statins.

Professor David H Lawson
Chairman